Dermatologist Dr Corinne Maiolo detailed a recent case involving a 17‑year‑old male with severe inflammatory acne, highlighting how clascoterone cream can be added to a multimodal regimen.
Case overview and severity assessment
The teenager presented with numerous papules, pustules, and nodular lesions across the face and upper chest. Clinical grading placed him at the higher end of the inflammatory acne spectrum, indicating a need for more than a single‑agent therapy.
Standard evaluation noted no underlying hormonal disorder, and the patient reported prior use of over‑the‑counter benzoyl peroxide with limited benefit. The physician documented a history of occasional topical antibiotics, but lesions persisted.
Integrating clascoterone into a broader plan
In the described approach, clascoterone was combined with a low‑potency topical retinoid and a short course of oral antibiotics. The aim was to address bacterial colonization, keratinocyte turnover, and androgen‑driven sebum production simultaneously.
Clascoterone, a topical androgen‑receptor antagonist, works by blocking the binding of dihydrotestosterone within the pilosebaceous unit. This mechanism reduces sebum output without the systemic exposure associated with oral anti‑androgens.
Within four weeks, the patient showed a noticeable decline in the number of active pustules. By the eighth week, erythema had softened, and no new nodules appeared. The physician noted that the improvement was more rapid than with the retinoid alone.
Related: Doctors rush to access health records
These observations align with early clinical trial data, which reported a 30‑percent reduction in inflammatory lesion counts after 12 weeks of daily use.
The practical impact of this case extends beyond the numbers. For adolescents who struggle with the social and emotional toll of visible acne, a faster‑acting topical option can lessen the period of self‑consciousness. By targeting the hormonal driver locally, clascoterone may avoid the side‑effects that sometimes accompany systemic treatments, making it a more acceptable first line for many families.
Safety monitoring revealed only mild irritation at the application site in a minority of patients, consistent with the product’s labeling. No systemic adverse events were reported, supporting its suitability for younger patients.
Regulatory records show that the United States Food and Drug Administration granted approval for clascoterone in 2020 for patients twelve years and older. The approval was based on randomized studies that demonstrated both efficacy and a favorable tolerability profile.
Clinicians considering this option should counsel patients on proper application—once daily to clean, dry skin—and emphasize adherence. Combining the cream with gentle moisturizers can mitigate the occasional dryness noted in practice.
In settings where oral isotretinoin is reserved for refractory cases, clascoterone offers a middle ground that may delay or reduce the need for that more aggressive therapy.
